ACTR1A: A Potential Drug Target and Biomarker (G10121)

Target Name: ACTR1A

NCBI ID: G10121

ACTR1A

ACTR1A: A Potential Drug Target and Biomarker

ACTR1A, also known as SLC30A8, is a gene that encodes a protein involved in the regulation of cell adhesion and migration. The protein is expressed in many tissues and cells, including neural and epithelial cells, and is involved in the development and maintenance of tissues and organs, including the brain and spinal cord.

Recent studies have identified ACTR1A as a potential drug target for the treatment of various diseases, including neurological and psychiatric disorders. The protein has also been identified as a potential biomarker for monitoring disease progression and response to therapeutic interventions.

Diseases and Therapies

Actr1a has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. These disorders are characterized by the progressive loss of brain cells and the formation of beta-amyloid plaques, which are thought to contribute to the development and progression of these disorders.

One of the reasons why ACTR1A has been identified as a potential drug target is its involvement in the regulation of cell adhesion and migration. These processes are important for the development and maintenance of tissues and organs, including the brain and spinal cord. Therefore, alterations in cell adhesion and migration processes have been implicated in the development of various neurological and psychiatric disorders.

In addition to its role in cell adhesion and migration, ACTR1A has also been identified as a potential drug target for the treatment of various psychiatric disorders. Studies have shown that ACTR1A is involved in the regulation of neurotransmitter release and cell signaling, which is thought to play a role in the development and maintenance of psychiatric disorders.

Biomarkers

ACTR1A has also been identified as a potential biomarker for the diagnosis and monitoring of various psychiatric disorders. Studies have shown that ACTR1A is expressed in the brains of individuals with psychiatric disorders, and that alterations in ACTR1A levels may be associated with the development and progression of these disorders.

In addition to its potential as a drug target, ACTR1A has also been identified as a potential biomarker for the diagnosis of certain psychiatric disorders. For example, studies have shown that ACTR1A levels are decreased in individuals with major depressive disorder, and that this decrease is associated with the development of this disorder.

Conclusion

In conclusion, ACTR1A is a gene that encodes a protein involved in the regulation of cell adhesion and migration, and has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders. Its involvement in these processes makes it an attractive target for the development of new therapies for these disorders.

Furthermore, ACTR1A has also been identified as a potential biomarker for the diagnosis and monitoring of various psychiatric disorders. Its expression in the brains of individuals with psychiatric disorders makes it an promising tool for the diagnosis and monitoring of these disorders.

Overall, ACTR1A is a promising protein for the development of new therapies for various neurological and psychiatric disorders, and its potential as a biomarker for disease diagnosis and monitoring should be further explored.

Protein Name: Actin Related Protein 1A

Functions: Part of the ACTR1A/ACTB filament around which the dynactin complex is built. The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules

The "ACTR1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTR1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets